A randomized open-label clinical trial including 18 patients with T1DM showed that the addition of exenatide reduced insulin requirements in patients with new-onset disease, resulting in significant weight loss with no hypoglycemic risk [7]. Here, INS is linked to type 1 diabetes mellitus.